Emilia Romagna. Alba Brandes, direttore dell'Oncologia di Bellaria, nella Top Italian Women Scientists 2016 - Quotidiano Sanità
symposium article
The Effect of Re-operation on Survival in Patients with Recurrent Glioblastoma
Hypofractionated Radiotherapy for Pediatric Diffuse Intrinsic Pontine Glioma (DIPG): A Prospective Controlled Randomized Trial
Practical Management of Bevacizumab‐Related Toxicities in Glioblastoma
The Role of Cetuximab in Pre-Treated Refractory Patients with Metastatic Colorectal Cancer: Outcome Study in Clinical Practice
PDF) Treatment options for recurrent glioblastoma: pitfalls and future trends | Enrico Franceschi - Academia.edu
Treatment options for recurrent glioblastoma: pitfalls and future trends
I farmaci chemioterapici più usati - la Repubblica
PDF) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: A phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
L'oncologa arrivata a Bologna per sfidare i tumori al cervello È tra le scienziate Top italiane - PressReader
The role of gender in glioblastoma: does it matter?
The metastatic process: a kaleidoscope of concepts
Donati 8 letti elettrici al reparto di Oncologia del Sistema Nervoso Centrale dell'IRCCS Istituto delle Scienze Neurologiche di Bologna — AUSL di Bologna
Brain metastases from non-small-cell lung cancer: is there room for improvement?
News & Views
Il trattamento del tumore prostatIco avanzato castration-resistant
JCO paper
Bellaria - San Marino Academy | ©FSGC | Bellaria, 18 maggio … | Flickr
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls
Hakim Rossella, MD, PhD | ior
I tumori rarissimi al cervello - PressReader
Postsurgical Approaches in Low‐Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Post-therapy neuronal maturation in an adult SHH medulloblastoma.
PDF) Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?
